Literature DB >> 4011532

Amiodarone and chronic lung fibrosis.

M J Finnegan, E B Faragher.   

Abstract

A covariate analysis was performed on the major lung function indices that are affected by pulmonary fibrosis in 29 patients who had recently started amiodarone therapy and compared with those of a group of 41 patients who had been treated for a mean of 19.6 months. Patients with other factors which affect gas transfer were excluded. A trend towards reduction in transfer factor, transfer coefficient and membrane diffusion was detected but did not reach statistical significance. A lower than expected incidence of acute pulmonary fibrosis was observed. In the treated group, there was no deterioration of transfer factor, transfer coefficient or membrane diffusion with either increasing duration of therapy or total dose taken.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4011532      PMCID: PMC2418421          DOI: 10.1136/pgmj.61.716.497

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  2 in total

1.  Subacute pneumopathy during amiodarone therapy.

Authors:  L D Suárez; J J Poderoso; B Elsner; A M Bunster; H Esteva; M Bellotti
Journal:  Chest       Date:  1983-03       Impact factor: 9.410

2.  Amiodarone pulmonary toxicity.

Authors:  F E Marchlinski; T S Gansler; H L Waxman; M E Josephson
Journal:  Ann Intern Med       Date:  1982-12       Impact factor: 25.391

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.